MARKET

RETA

RETA

Reata Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

135.37
+2.60
+1.96%
Closed 16:00 04/02 EDT
OPEN
131.36
PREV CLOSE
132.77
HIGH
137.29
LOW
129.00
VOLUME
319.81K
TURNOVER
--
52 WEEK HIGH
257.97
52 WEEK LOW
70.00
MARKET CAP
4.50B
P/E (TTM)
-14.4833
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RETA stock price target is 275.50 with a high estimate of 335.00 and a low estimate of 172.00.

EPS

RETA News

More
  • This Highflying Biotech Stock Tumbled After Shuttering Two Key Studies
  • Investor's Business Daily · 2d ago
  • Baird Maintains Outperform on Reata Pharmaceuticals, Lowers Price Target to $268
  • Benzinga · 2d ago
  • Stifel Maintains Buy on Reata Pharmaceuticals, Lowers Price Target to $315
  • Benzinga · 2d ago
  • The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions
  • Benzinga · 2d ago

Industry

Biotechnology & Medical Research
+3.33%
Pharmaceuticals & Medical Research
+2.80%

Hot Stocks

Symbol
Price
%Change

About RETA

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia, mitochondrial myopathies and metastatic melanoma.
More

Webull offers kinds of Reata Pharmaceuticals Inc stock information, including NASDAQ:RETA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RETA stock news, and many more online research tools to help you make informed decisions.